Back
Dermata Therapeutics Inc (DRMA)
BiotechnologyDRMA · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$1.10
−0.45%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$-8.16
ROE
-103.6%
Gross margin
0.0%
Debt/Equity
Revenue growth
P/B ratio
Beta
Forward P/E
Dermata Therapeutics Inc — company intelligence
Earnings surprises
Q2 2026$-0.74 vs $-0.56 est-31.9%
Q1 2026$-0.48 vs $-0.54 est+11.2%
Q4 2025$-1.52 vs $-1.57 est+3.2%
Q3 2025$-1.65 vs $-1.62 est-1.7%
Analyst consensus · 7 analysts
6 Buy1 Hold0 Sell
Updated Oct 4, 2026
Recent SEC filings
4 — Insider transaction reportAug 18, 2026
4 — Insider transaction reportAug 18, 2026
8-K — Material event reportAug 17, 2026
Latest news
12 Health Care Stocks Moving In Tuesday's After-Market Session — Benzinga · Sep 8, 2026
Papulopustular Rosacea Market Report Now Available, Covers 11 Countries Across North America, Europe, and Asia-Pacific, Profiling Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's Laboratories — Yahoo · Aug 31, 2026
Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment — Yahoo · Aug 25, 2026
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.